Biosimilar Interleukins Market Report 2025

This Biosimilar Interleukins market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $3.9 billion in 2024 to $5.41 billion in 2025 at a compound annual growth rate (CAGR) of 39%. The growth in the historic period can be attributed to the rising prevalence of autoimmune diseases, increasing awareness of biosimilar interleukins, growing government support for biosimilars, expansion of the biosimilar, and increasing patient demand for biosimilars.

The biosimilar interleukins market size is expected to see exponential growth in the next few years. It will grow to $20.79 billion in 2029 at a compound annual growth rate (CAGR) of 40%. The growth in the forecast period can be attributed to the growing patient population, increased access to healthcare, growing demand for personalized medicine, and growing demand for minimally invasive procedures. Major trends in the forecast period include advances in biosimilar technology, targeted immunotherapies, quality control and manufacturing, and global collaboration.

The rising prevalence of autoimmune diseases, such as psoriasis and rheumatoid arthritis, is anticipated to enhance the growth of the interleukin biosimilars market during the forecast period. Autoimmune disorders occur when immune cells fail to differentiate between healthy cells and potentially harmful antibodies. Biologic drugs, including anti-interleukin antibodies, have demonstrated significant clinical advantages in regulating these immune cells and managing their proliferation, activation, and migration. For instance, in February 2024, reports from the National Institutes of Health (NIH), a U.S.-based biomedical research agency, indicated that the global incidence and prevalence of autoimmune diseases are projected to increase annually by 19.1% and 12.5%, respectively. As a result, the growing prevalence of autoimmune diseases is driving demand for biosimilar interleukins and is expected to propel market growth.

The increasing prevalence of arthritis is expected to drive the growth of the biosimilar interleukins market. Arthritis refers to pain or inflammation affecting the joints, which can involve swelling in one or more joints. Biosimilars, including interleukins, are utilized in the treatment of various inflammatory and autoimmune disorders such as rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. For example, in February 2024, reports from the Centers for Disease Control and Prevention (CDC), a U.S.-based public health agency, indicated that in 2022, the age-adjusted rate of adults living with arthritis was 18.9%. Consequently, the rising prevalence of arthritis is projected to further accelerate the growth of the biosimilar interleukins market in the future.

Key players in the biosimilar interleukins market are introducing innovative products like Tofidence (tocilizumab-bavi) to bolster their profitability in the market. Tofidence, a monoclonal antibody targeting and binding to interleukin-6 receptors, serves in treating various inflammatory autoimmune disorders. In September 2023, Biogen, a US-based biotechnology company, received FDA approval for Tofidence (tocilizumab-bavi) as the initial biosimilar to Genentech's Actemra (tocilizumab). Administered via intravenous infusion, Tofidence has gained approval for treating severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis, marking a strategic move to enhance their market presence and profitability.

In February 2022, Equillium, a biotechnology company based in the United States, acquired Bioniz Therapeutics, Inc. for $329 million. This acquisition significantly expands Equillium's portfolio of innovative immunomodulatory drug candidates by providing access to three established therapeutics and additional assets currently in the discovery phase. Bioniz Therapeutics, Inc. is also a biotechnology company located in the U.S.

Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

Biosimilar interleukins refer to proteins produced by the body's white blood cells, known as leukocytes. These interleukins play a crucial role in regulating immune responses. Laboratory-generated interleukins are utilized as biological response modifiers to fortify the immune system, particularly in cancer treatment.

Various types of biosimilar interleukins include IL-17, IL-23, IL-1, IL-5, IL-6, among others. For instance, Interleukin 17 belongs to the pro-inflammatory cystine knot cytokine family and is produced by a specific subset of T helper cells, known as T helper 17 cells, in response to IL-23 stimulation. These biosimilar interleukins find diverse applications in treating conditions such as psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), and other immune-related disorders. They are made available through various distribution channels, including hospital pharmacies, online pharmacies, retail pharmacies, clinics, as well as research institutes, catering to different healthcare settings and patient needs.

The biosimilar interleukins market research report is one of a series of new reports that provides biosimilar interleukins market statistics, including biosimilar interleukins industry global market size, regional shares, competitors with a biosimilar interleukins market share, detailed biosimilar interleukins market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar interleukins industry. The biosimilar interleukins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

North America was the largest region in the biosimilar interleukins market in 2024. The regions covered in the biosimilar interleukins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The biosimilar interleukins market consists of sales of mabPharm, gedeonrichter, and bio-thera solutions. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.